[en] The data from this trial will provide insight into the safety and efficacy of the combination of EVE and EXE versus EVE or capecitabine monotherapy in women with ER+, HER2- ABC progressing on/after prior LET or ANA.
Disciplines :
Oncology
Author, co-author :
Ejlertsen, Bent; Copenhagen University Hospital, Copenhagen, Denmark
JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Hurvitz, Sara; UCLA Medical Center, Los Angeles, California, USA
de Boer, Richard; Royal Melbourne Hospital, Melbourne, Australia
Taran, Tetiana; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Sahmoud, Tarek; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Burris, Howard; Sarah Cannon Research Institute, Nashville, Tennessee, USA
Language :
English
Title :
Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6
